<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)
<i>Granulibacter bethesdensis</i> can infect patients with chronic granulomatous disease, an immunodeficiency caused by reduced phagocyte NADPH oxidase function. Intact <i>G. bethesdensis</i> (<i>Gb</i>) is hypostimulatory compared to <i>Escherichia coli<...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/7/3303 |
id |
doaj-7742a9e28acd472eb3687d321e9e745a |
---|---|
record_format |
Article |
spelling |
doaj-7742a9e28acd472eb3687d321e9e745a2021-03-25T00:01:06ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-03-01223303330310.3390/ijms22073303<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)Artur Muszyński0Kol A. Zarember1Christian Heiss2Joseph Shiloach3Lars J. Berg4John Audley5Arina Kozyr6David E. Greenberg7Steven M. Holland8Harry L. Malech9Parastoo Azadi10Russell W. Carlson11John I. Gallin12Complex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USABiotechnology Core, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USAComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA<i>Granulibacter bethesdensis</i> can infect patients with chronic granulomatous disease, an immunodeficiency caused by reduced phagocyte NADPH oxidase function. Intact <i>G. bethesdensis</i> (<i>Gb</i>) is hypostimulatory compared to <i>Escherichia coli</i>, i.e., cytokine production in human blood requires 10–100 times more <i>G. bethesdensis</i> CFU/mL than <i>E. coli</i>. To better understand the pathogenicity of <i>G. bethesdensis</i>, we isolated its lipopolysaccharide (<i>Gb</i>LPS) and characterized its lipid A. Unlike with typical <i>Enterobacteriaceae</i>, the release of presumptive Gb lipid A from its LPS required a strong acid. NMR and mass spectrometry demonstrated that the carbohydrate portion of the isolated glycolipid consists of α-Man<i>p</i>-(1→4)-β-Glc<i>p</i>N3N-(1→6)-α-Glc<i>p</i>N-(1⇿1)-α-Glc<i>p</i>A tetra-saccharide substituted with five acyl chains: the amide-linked N-3′ 14:0(3-OH), N-2′ 16:0(3-O16:0), and N-2 18:0(3-OH) and the ester-linked O-3 14:0(3-OH) and 16:0. The identification of glycero-d-talo-oct-2-ulosonic acid (Ko) as the first constituent of the core region of the LPS that is covalently attached to GlcpN3N of the lipid backbone may account for the acid resistance of <i>Gb</i>LPS. In addition, the presence of Ko and only five acyl chains may explain the >10-fold lower proinflammatory potency of <i>Gb</i>Ko–lipidA compared to <i>E. coli</i> lipid A, as measured by cytokine induction in human blood. These unusual structural properties of the <i>G.bethesdensis</i> Ko–lipid A glycolipid likely contribute to immune evasion during pathogenesis and resistance to antimicrobial peptides.https://www.mdpi.com/1422-0067/22/7/3303lipopolysaccharidelipid AGram-negative pathogen, immunodeficiency |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Artur Muszyński Kol A. Zarember Christian Heiss Joseph Shiloach Lars J. Berg John Audley Arina Kozyr David E. Greenberg Steven M. Holland Harry L. Malech Parastoo Azadi Russell W. Carlson John I. Gallin |
spellingShingle |
Artur Muszyński Kol A. Zarember Christian Heiss Joseph Shiloach Lars J. Berg John Audley Arina Kozyr David E. Greenberg Steven M. Holland Harry L. Malech Parastoo Azadi Russell W. Carlson John I. Gallin <i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) International Journal of Molecular Sciences lipopolysaccharide lipid A Gram-negative pathogen, immunodeficiency |
author_facet |
Artur Muszyński Kol A. Zarember Christian Heiss Joseph Shiloach Lars J. Berg John Audley Arina Kozyr David E. Greenberg Steven M. Holland Harry L. Malech Parastoo Azadi Russell W. Carlson John I. Gallin |
author_sort |
Artur Muszyński |
title |
<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_short |
<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_full |
<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_fullStr |
<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_full_unstemmed |
<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_sort |
<i>granulibacter bethesdensis</i>, a pathogen from patients with chronic granulomatous disease, produces a penta-acylated hypostimulatory glycero-d-talo-oct-2-ulosonic acid–lipid a glycolipid (ko-lipid a) |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-03-01 |
description |
<i>Granulibacter bethesdensis</i> can infect patients with chronic granulomatous disease, an immunodeficiency caused by reduced phagocyte NADPH oxidase function. Intact <i>G. bethesdensis</i> (<i>Gb</i>) is hypostimulatory compared to <i>Escherichia coli</i>, i.e., cytokine production in human blood requires 10–100 times more <i>G. bethesdensis</i> CFU/mL than <i>E. coli</i>. To better understand the pathogenicity of <i>G. bethesdensis</i>, we isolated its lipopolysaccharide (<i>Gb</i>LPS) and characterized its lipid A. Unlike with typical <i>Enterobacteriaceae</i>, the release of presumptive Gb lipid A from its LPS required a strong acid. NMR and mass spectrometry demonstrated that the carbohydrate portion of the isolated glycolipid consists of α-Man<i>p</i>-(1→4)-β-Glc<i>p</i>N3N-(1→6)-α-Glc<i>p</i>N-(1⇿1)-α-Glc<i>p</i>A tetra-saccharide substituted with five acyl chains: the amide-linked N-3′ 14:0(3-OH), N-2′ 16:0(3-O16:0), and N-2 18:0(3-OH) and the ester-linked O-3 14:0(3-OH) and 16:0. The identification of glycero-d-talo-oct-2-ulosonic acid (Ko) as the first constituent of the core region of the LPS that is covalently attached to GlcpN3N of the lipid backbone may account for the acid resistance of <i>Gb</i>LPS. In addition, the presence of Ko and only five acyl chains may explain the >10-fold lower proinflammatory potency of <i>Gb</i>Ko–lipidA compared to <i>E. coli</i> lipid A, as measured by cytokine induction in human blood. These unusual structural properties of the <i>G.bethesdensis</i> Ko–lipid A glycolipid likely contribute to immune evasion during pathogenesis and resistance to antimicrobial peptides. |
topic |
lipopolysaccharide lipid A Gram-negative pathogen, immunodeficiency |
url |
https://www.mdpi.com/1422-0067/22/7/3303 |
work_keys_str_mv |
AT arturmuszynski igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT kolazarember igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT christianheiss igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT josephshiloach igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT larsjberg igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT johnaudley igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT arinakozyr igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT davidegreenberg igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT stevenmholland igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT harrylmalech igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT parastooazadi igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT russellwcarlson igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT johnigallin igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida |
_version_ |
1724204305110532096 |